Heather Payne

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1493778/publications.pdf

Version: 2024-02-01

40	802	687363	501196
papers	citations	13 h-index	28 g-index

40	40	40	1351
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Determinants of variation in radical local treatment for men with high-risk localised or locally advanced prostate cancer in England. Prostate Cancer and Prostatic Diseases, 2023, 26, 257-263.	3.9	6
2	Comparison of the treatment of men with prostate cancer between the US and England: an international population-based study. Prostate Cancer and Prostatic Diseases, 2023, 26, 287-292.	3.9	3
3	A European, prospective, observational study of enzalutamide in patients with metastatic castrationâ€resistant prostate cancer: PREMISE. International Journal of Cancer, 2022, 150, 837-846.	5.1	14
4	Urinary incontinence and use of incontinence surgery after radical prostatectomy: a national study using patientâ€reported outcomes. BJU International, 2022, 130, 84-91.	2.5	11
5	Establishing metastatic prostate cancer quality indicators using a modified Delphi approach. Clinical Genitourinary Cancer, 2022, , .	1.9	1
6	Magnetic Resonance Imaging and Targeted Biopsies Compared to Transperineal Mapping Biopsies Before Focal Ablation in Localised and Metastatic Recurrent Prostate Cancer After Radiotherapy. European Urology, 2022, 81, 598-605.	1.9	9
7	Interventions for obstructive uropathy in advanced prostate cancer: a populationâ€based study. BJU International, 2022, , .	2.5	1
8	Management of newly diagnosed metastatic hormoneâ€sensitive prostate cancer: A survey of UK Uroâ€oncologists. International Journal of Clinical Practice, 2021, 75, e13874.	1.7	0
9	Impact of High-Dose-Rate and Low-Dose-Rate Brachytherapy Boost on Toxicity, Functional and Cancer Outcomes in Patients Receiving External Beam Radiation Therapy for Prostate Cancer: A National Population-Based Study. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1219-1229.	0.8	13
10	Patient-reported functional outcomes following external beam radiation therapy for prostate cancer with and without a high-dose rate brachytherapy boost: A national population-based study. Radiotherapy and Oncology, 2021, 155, 48-55.	0.6	6
11	Public reporting of outcomes in radiation oncology: the National Prostate Cancer Audit. Lancet Oncology, The, 2021, 22, e207-e215.	10.7	20
12	Rectal spacers in patients with prostate cancer undergoing radiotherapy: A survey of UK uroâ€oncologists. International Journal of Clinical Practice, 2021, 75, e14338.	1.7	1
13	Re: David W. Donnelly, Anna Gavin, Amy Downing, et al. Regional Variations in Quality of Survival Among Men with Prostate Cancer Across the United Kingdom. Eur Urol 2019;76:228â€“37. European Urology, 2020, 77, e65.	1.9	0
14	Patient-Reported Functional Outcomes After Hypofractionated or Conventionally Fractionated Radiation for Prostate Cancer: A National Cohort Study in England. Journal of Clinical Oncology, 2020, 38, 744-752.	1.6	14
15	Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet, The, 2020, 396, 1413-1421.	13.7	226
16	Use of bisphosphonates and other bone supportive agents in the management of prostate cancerâ€”A UK perspective. International Journal of Clinical Practice, 2020, 74, e13611.	1.7	0
17	Toxicity of Pelvic Lymph Node Irradiation With Intensity Modulated Radiation Therapy for High-Risk and Locally Advanced Prostate Cancer: A National Population-Based Study Using Patient-Reported Outcomes. International Journal of Radiation Oncology Biology Physics, 2020, 108, 1196-1203.	0.8	10
18	Patientsâ€™ and partnersâ€™ views of care and treatment provided for metastatic castrateâ€resistant prostate cancer in the UK. European Journal of Cancer Care, 2019, 28, e13140.	1.5	7

#	Article	IF	Citations
19	Identifying skeletal-related events for prostate cancer patients in routinely collected hospital data. Cancer Epidemiology, 2019, 63, 101628.	1.9	15
20	Measuring testosterone and testosterone replacement therapy in men receiving androgen deprivation therapy for prostate cancer: A survey of UK uroâ€oncologists' opinions and practice. International Journal of Clinical Practice, 2019, 73, 1-6.	1.7	3
21	Imputation of missing prostate cancer stage in English cancer registry data based on clinical assumptions. Cancer Epidemiology, 2019, 58, 44-51.	1.9	11
22	Impact of cancer service centralisation on the radical treatment of men with highâ€risk and locally advanced prostate cancer: A national crossâ€sectional analysis in England. International Journal of Cancer, 2019, 145, 40-48.	5.1	16
23	Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey. European Urology Focus, 2018, 4, 235-244.	3.1	14
24	Impact of ⁶⁸Ga-Prostate-Specific Membrane Antigen PET/CT on Prostate Cancer Management. Journal of Nuclear Medicine, 2018, 59, 89-92.	5.0	58
25	National cohort study comparing severe mediumâ€term urinary complications after robotâ€assisted vs laparoscopic vs retropubic open radical prostatectomy. BJU International, 2018, 121, 445-452.	2.5	18
26	Treatment-related toxicity in men who received Intensity-modulated versus 3D-conformal radiotherapy after radical prostatectomy: A national population-based study. Radiotherapy and Oncology, 2018, 128, 357-363.	0.6	9
27	Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology. European Urology, 2017, 72, 521-531.	1.9	174
28	Quantifying severe urinary complications after radical prostatectomy: the development and validation of a surgical performance indicator using hospital administrative data. BJU International, 2017, 120, 219-225.	2.5	10
29	National Population-Based Study Comparing Treatment-Related Toxicity in Men Who Received Intensity Modulated Versus 3-Dimensional Conformal Radical Radiation Therapy for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, 1253-1260.	0.8	38
30	Patient-reported outcomes in metastatic castration-resistant prostate cancer. Nature Reviews Clinical Oncology, 2016, 13, 643-650.	27.6	27
31	Advances in advanced prostate cancer â€“ the continuing journey. BJU International, 2016, 118, 17-19.	2.5	0
32	Management of Node-Positive Bladder Cancer After Neoadjuvant Chemotherapy and Radical Cystectomy: A Survey of Current UK Practice. Clinical Genitourinary Cancer, 2015, 13, e153-e158.	1.9	10
33	Anorectal toxicity of external beam radiotherapy in the treatment of prostate cancer. Journal of Clinical Urology, 2014, 7, 185-189.	0.1	0
34	Second-line chemotherapy for advanced bladder cancer: A survey of current UK practice. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 52.e11-52.e17.	1.6	1
35	Comparision of the risk of cardiovascular events and death in patients treated with degarelix compared with LHRH agonists.. Journal of Clinical Oncology, 2013, 31, 42-42.	1.6	4
36	Current management and proposal for guidance of radiation cystitis (RC): Results of a British Uro-oncology Group (BUG) survey.. Journal of Clinical Oncology, 2013, 31, 297-297.	1.6	0

#	Article	IF	Citations
37	Prostate-specific antigen: An evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 593-601.	1.6	38
38	Easing the journey through prostate cancer. British Journal of Health Care Management, 2010, 16, 129-133.	0.2	0
39	Management of locally advanced prostate cancer. Asian Journal of Andrology, 2009, 11, 81-87.	1.6	13
40	RADIATION IN HIGHâ€RISK PROSTATE CANCER: HOW MUCH IS ENOUGH?. BJU International, 2008, 102, 663-665.	2.5	1